Dr. Marty Makary has left his role as commissioner of the Food and Drug Administration, a move that lands after weeks of controversy in Washington and follows policy shifts like the authorization of fruit-flavored e-cigarettes and an unresolved review of the abortion medication mifepristone. His exit, reported by multiple outlets and tied to White House dissatisfaction, comes amid a year of high-profile departures from the Trump administration and raises fresh questions about leadership at the FDA and the administration’s agenda.
The departure of Makary is the latest shake-up in an administration that promised bold change and has delivered on some campaign pledges while clashing with its own appointees. He had been a visible figure after being nominated to lead the FDA and frequently drew attention for his prior critiques of COVID policy and his academic background. For Republicans who expected decisive action on regulatory issues, his exit looks like a course correction by the White House.
One flashpoint was the FDA decision to allow fruit-flavored vapes for adults, a reversal that aligned with President Donald Trump’s campaign promise to restore those products to the market. Industry pressure and political priorities converged, and the agency moved to authorize flavored e-cigarettes for adult smokers. Supporters of the move argued it respects adult consumer choice and could reduce harm by offering alternatives to combustible cigarettes.
At the same time, Makary faced pressure from Republicans over a promised review of mifepristone, the abortion pill. During his confirmation he said the FDA would reexamine the medication’s safety and the rules around mailing and telehealth dispensing. That review never produced a public decision before his departure, and critics in Congress grew frustrated with the pace and transparency of the process.
The Supreme Court stepped in earlier this month with a temporary decision that maintained nationwide access to mifepristone while lower court rulings were sorted out. That ruling kept mail and telehealth access intact for now, even as lawmakers and the administration debated the FDA’s next moves. The unresolved federal legal questions added pressure on the agency and on Makary as commissioner.
Reports also tied Makary’s handling of the mifepristone review to political timing, with allegations that he sought to delay a study until after elections. Whether those reports are accurate or not, the episode underscored a larger concern for Republicans: an agency leader who fails to deliver timely answers on high-stakes issues invites criticism and weakens policy discipline. The administration, keen to keep campaign promises and respond to conservative lawmakers, appeared to conclude new leadership would better match its priorities.
Marty Makary’s background is unmistakable — a longtime surgeon at Johns Hopkins Hospital and a professor emeritus at the Johns Hopkins School of Medicine before moving into government. His reputation as an outspoken academic and a critic of some pandemic measures made him a controversial but prominent pick for the job. That pedigree gave him credibility with some, but it also set high expectations for his ability to navigate both science and politics in a sensitive federal role.
This exit follows several other notable departures from the administration this year, illustrating a clear pattern of personnel turnover at the top. Since January, Kristi Noem and Pam Bondi were removed from their posts, and Lori Chavez DeRemer resigned amid a separate probe in April. For Republicans watching the White House carefully, the churn reflects a willingness by the president to reshuffle personnel to keep policy trajectories aligned with campaign promises and legislative goals.
What happens next at the FDA matters for public health policy and for the administration’s broader agenda. The agency will need steady leadership to manage product authorizations, respond to legal challenges, and restore confidence among allies in Congress. For those in the GOP who want quick, decisive action on regulatory fronts, the hope will be that the next commissioner moves faster and with closer coordination with the White House.
